SOURCE: Syneron Medical

February 05, 2007 07:00 ET

Syneron and Obagi Medical to Initiate Collaboration Aimed at Improved Patient Outcomes in Aesthetic Medical Procedures

YOKNEAM, ISRAEL and TORONTO -- (MARKET WIRE) -- February 5, 2007 -- Syneron Medical Ltd. (NASDAQ: ELOS), an innovator in the development, marketing and sales of elos™ combined-energy medical aesthetic devices, today announced the initiation of a multi-center clinical study with Obagi Medical Products, Inc. (NASDAQ: OMPI), a California-based company, and a leader in aesthetic and therapeutic skin health care.

As part of the study, doctors who are actively performing Syneron elos procedures will begin evaluating Obagi's newly developed Nu-Derm Condition and Enhance™ skin care systems, prior to or following elos treatments to measure improvement in overall patient outcome for the treatment of fine lines, photo damage and hyper-pigmented skin attributable to the combination therapy.

"The collaboration with Obagi will increase Syneron's market exposure to plastic surgeons and strengthen Syneron's position as the leader in the aesthetic market," said Doron Gerstel, President of Syneron North America. "We are delighted that Obagi has recognized Syneron as a leader in our market, and we look forward to a successful clinical study and future collaboration on new product development."

"Energy-based skin rejuvenation treatments have a strong and growing presence among cosmetic and plastic surgeons," said Steve Carlson President and CEO of Obagi Medical Products, Inc. "Given Syneron's innovative technology and understanding of this space, they are an ideal partner to undertake this study. Our goal is to demonstrate the advantages of adding complementary topical treatments to existing medical aesthetic procedures in order to improve patient outcomes."

About Syneron

Syneron Medical Ltd. (NASDAQ: ELOS) manufactures and distributes medical aesthetic devices that are powered by the proprietary, patented elos combined-energy technology of Bi-Polar Radio Frequency and Light. The Company's innovative elos technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.

About Obagi Medical Products, Inc.

Obagi Medical Products is a specialty pharmaceutical company that develops and commercializes innovative products for the dermatology, plastic surgery and related aesthetic and therapeutic markets. Using its Penetrating Therapeutics™ technologies, Obagi's products are uniquely designed to improve penetration of agents across the skin barrier for the prevention and correction of the most common skin disorders in adult skin such as chloasma, melasma, senile letigines, acne vulgaris and sun damage. Obagi launched its first skincare system, Obagi-Nu-Derm, in 1988; and in 2004 launched the first and only prescription strength Vitamin C and hydroquinone system, Obagi-C Rx System. Obagi System products are only available through physicians, which include over 3,500 in the U.S., primarily dermatologists and plastic surgeons, medical spas and other skin care specialists.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 relating to future events or our future performance, including statements with respect to our expectations regarding improved patient outcomes, increased marketing exposure to plastic surgeons, and the development of new products. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in those forward-looking statements. These risks and other factors are summarized under the heading "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2005, filed with the Securities and Exchange Commission on June 30, 2006. These factors are updated from time to time through the filing of reports and registration statements with the Securities and Exchange Commission. We do not assume any obligation to update the forward-looking information contained in this press release.

Contact Information

  • For more information, please contact:

    David Seligman
    CFO
    +972 54 772 6559
    email: cfo@syneron.com

    Judith Kleinman
    VP Investor Relations
    +972-4-909-6282
    email: ir@syneron.com

    Nick Laudico
    IR consultant
    The Ruth Group (U.S. contact)
    646 734 4792
    email: nlaudico@theruthgroup.com

    Elin Spahr
    Airfoil Public Relations for Syneron Medical Ltd.
    (248) 304-1412
    email: spahr@airfoilpr.com